• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Investigation of blood lipid levels and statin interventions in outpatients with coronary heart disease in China: the China Cholesterol Education Program (CCEP).

作者信息

Hu Dayi, Li Jue, Li Xiankai

机构信息

Heart, Lung and Blood Vessel Center of Tongji University, Shanghai, China.

出版信息

Circ J. 2008 Dec;72(12):2040-5. doi: 10.1253/circj.cj-08-0417. Epub 2008 Oct 21.

DOI:10.1253/circj.cj-08-0417
PMID:18946170
Abstract

BACKGROUND

The aim of the China Cholesterol Education Program is to investigate the blood lipid levels, the statin intervention and the rates of achieving the goal of low-density lipoprotein-cholesterol (LDL-C) level in Chinese outpatients with coronary heart disease (CHD).

METHODS AND RESULTS

The multicenter study recruited 4,778 outpatients with CHD. The mean level of LDL-C for the total outpatients was 2.93+/-1.00 mmol/L; 82.2% of the participants received statin therapy. The LDL-C levels were 3.06+/-1.08 mmol/L and 2.89+/-0.97 mmol/L in outpatients with high risk and very high risk, respectively (p<0.001). No significant difference was found about the rates of statin intervention in outpatients at high risk and very high risk (81.4% vs 82.5%, p>0.05). Though they had higher rates of statin intervention, only 36.2% of the high-risk outpatients achieved the target LDL-C level (<2.6 mmol/L); 10.9% of the very high risk outpatients achieved the optimal LDL-C level (<1.82 mmol/L) suggested by NCEP ATP III. The rate of achieving the target level was only 42.2%, even though LDL-C <2.6mmol/L was the goal for patients at very high risk.

CONCLUSIONS

Although the outpatients received a higher rate of statin therapy, the rates of achieving the target cholesterol level were lower. There is a significant gap between the guidelines and clinical practice in China.

摘要

相似文献

1
Investigation of blood lipid levels and statin interventions in outpatients with coronary heart disease in China: the China Cholesterol Education Program (CCEP).
Circ J. 2008 Dec;72(12):2040-5. doi: 10.1253/circj.cj-08-0417. Epub 2008 Oct 21.
2
The gender differences in baseline characteristics and statin intervention among outpatients with coronary heart disease in China: the China Cholesterol Education Program.中国冠心病门诊患者的基线特征和他汀类药物干预的性别差异:中国胆固醇教育计划。
Clin Cardiol. 2009 Jun;32(6):308-14. doi: 10.1002/clc.20514.
3
Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.来自24个欧洲国家的冠心病患者的降脂药物治疗——EUROASPIRE IV调查结果
Atherosclerosis. 2016 Mar;246:243-50. doi: 10.1016/j.atherosclerosis.2016.01.018. Epub 2016 Jan 13.
4
Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.降脂治疗与中国福州高危心血管风险患者的低密度脂蛋白胆固醇(LDL-C)目标达标情况。
J Cardiovasc Pharmacol Ther. 2020 Jul;25(4):307-315. doi: 10.1177/1074248419899298. Epub 2020 Jan 10.
5
Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.在高或极高心血管风险患者中他汀类药物的应用和血脂目标达标情况:来自意大利普通实践的见解。
Atherosclerosis. 2018 Apr;271:120-127. doi: 10.1016/j.atherosclerosis.2018.02.024. Epub 2018 Feb 17.
6
Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.在高和极高心血管风险患者中使用调脂治疗和降低低密度脂蛋白胆固醇目标达标情况:来自德国的真实世界证据。
Atherosclerosis. 2018 Jan;268:99-107. doi: 10.1016/j.atherosclerosis.2017.11.020. Epub 2017 Nov 20.
7
Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.在老年患者中,依折麦布联合他汀类药物持续治疗对改善血脂谱及实现低密度脂蛋白胆固醇目标的有效性:一项随机、双盲、安慰剂对照试验数据的亚组分析
Am J Geriatr Pharmacother. 2005 Dec;3(4):218-28.
8
[Achieving optimal cholesterol levels in patients with chronic ischemic heart disease: from guidelines to the real world].[在慢性缺血性心脏病患者中实现最佳胆固醇水平:从指南到现实世界]
G Ital Cardiol (Rome). 2015 Apr;16(4):240-9. doi: 10.1714/1848.20190.
9
Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men.与男性相比,在接受他汀类药物治疗的女性中,心血管疾病预防方面仍然存在性别差异。
Nutr Metab Cardiovasc Dis. 2018 Aug;28(8):810-815. doi: 10.1016/j.numecd.2018.03.012. Epub 2018 Apr 7.
10
AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).AMG 145,一种针对 PCSK9 的单克隆抗体,可帮助高危患者实现国家胆固醇教育计划成人治疗专家组 III 低密度脂蛋白胆固醇目标:来自 LAPLACE-TIMI 57 试验的分析(使用 PCSK9 单克隆抗体抑制联合他汀类药物治疗进行 LDL-C 评估 - 心肌梗死溶栓治疗 57)。
J Am Coll Cardiol. 2014 Feb 11;63(5):430-3. doi: 10.1016/j.jacc.2013.09.048. Epub 2013 Oct 23.

引用本文的文献

1
Cardioprotective medication adherence among patients with coronary heart disease in China: a systematic review.中国冠心病患者的心脏保护药物依从性:一项系统评价
Heart Asia. 2019 Jun 24;11(2):e011173. doi: 10.1136/heartasia-2018-011173. eCollection 2019.
2
Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and the CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomised controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes.心血管健康与短信(CHAT)研究和 CHAT-糖尿病(CHAT-DM)研究的设计和原理:两项随机对照试验,通过短信改善冠心病和糖尿病的二级预防。
BMJ Open. 2017 Dec 21;7(12):e018302. doi: 10.1136/bmjopen-2017-018302.
3
Cardiovascular diseases in China: Current status and future perspectives.
中国的心血管疾病:现状与未来展望。
Int J Cardiol Heart Vasc. 2014 Dec 30;6:25-31. doi: 10.1016/j.ijcha.2014.10.002. eCollection 2015 Mar 1.
4
Factors associated with lipid goal attainment among acute coronary syndrome patients.急性冠状动脉综合征患者血脂目标达成的相关因素
Patient Prefer Adherence. 2016 Aug 24;10:1631-7. doi: 10.2147/PPA.S110419. eCollection 2016.
5
The specialty of pulmonary vascular medicine in China: historical development and future directions.中国肺血管医学专业:历史发展与未来方向。
Cardiovasc Diagn Ther. 2012 Sep;2(3):240-5. doi: 10.3978/j.issn.2223-3652.2012.07.05.
6
Factors associated with blood pressure control in hypertensive patients with coronary heart disease: evidence from the Chinese Cholesterol Education Program.与冠心病高血压患者血压控制相关的因素:来自中国胆固醇教育计划的证据。
PLoS One. 2013 May 15;8(5):e63135. doi: 10.1371/journal.pone.0063135. Print 2013.
7
Barriers to translating EU and US CVD guidelines into practice in China.将欧盟和美国心血管疾病指南转化为中国实践的障碍。
Nat Rev Cardiol. 2012 May 1;9(7):425-9. doi: 10.1038/nrcardio.2012.62.